SG Americas Securities’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-26,042
| Closed | -$1.88M | – | 3625 |
|
|
2025
Q4 | $1.88M | Sell |
26,042
-274
| -1% | -$17.7K | ﹤0.01% | 1569 |
|
|
2025
Q3 | $1.15M | Buy |
26,316
+4,386
| +20% | +$177K | ﹤0.01% | 1336 |
|
|
2025
Q2 | $623K | Buy |
21,930
+4,440
| +25% | +$132K | ﹤0.01% | 1502 |
|
|
2025
Q1 | $516K | Buy |
+17,490
| New | +$545K | ﹤0.01% | 1750 |
|
|
2024
Q4 | – | Sell |
-12,675
| Closed | -$582K | – | 3540 |
|
|
2024
Q3 | $582K | Sell |
12,675
-83,604
| -87% | -$3.63M | ﹤0.01% | 1552 |
|
|
2024
Q2 | $3.93M | Buy |
96,279
+91,870
| +2,084% | +$2.64M | 0.02% | 665 |
|
|
2024
Q1 | $113K | Sell |
4,409
-37,296
| -89% | -$584K | ﹤0.01% | 2467 |
|
|
2023
Q4 | $377K | Buy |
+41,705
| New | +$279K | ﹤0.01% | 1654 |
|
|
2023
Q2 | – | Sell |
-26,097
| Closed | -$401K | – | 3030 |
|
|
2023
Q1 | $401K | Buy |
26,097
+7,406
| +40% | +$163K | ﹤0.01% | 1880 |
|
|
2022
Q4 | $415K | Buy |
18,691
+1,635
| +10% | +$24.4K | 0.01% | 1680 |
|
|
2022
Q3 | $279K | Sell |
17,056
-14,069
| -45% | -$269K | ﹤0.01% | 2048 |
|
|
2022
Q2 | $452K | Buy |
+31,125
| New | +$463K | ﹤0.01% | 2046 |
|
|
2022
Q1 | – | Sell |
-10,307
| Closed | -$245K | – | 3355 |
|
|
2021
Q4 | $245K | Sell |
10,307
-14,351
| -58% | -$343K | ﹤0.01% | 2561 |
|
|
2021
Q3 | $607K | Sell |
24,658
-2,843
| -10% | -$61.8K | ﹤0.01% | 2332 |
|
|
2021
Q2 | $680K | Sell |
27,501
-3,033
| -10% | -$70.6K | ﹤0.01% | 1788 |
|
|
2021
Q1 | $666K | Buy |
+30,534
| New | +$747K | ﹤0.01% | 1807 |
|
Other funds holding RNAM
SG Americas Securities's RNAM Position: Q1 2026 in Review
SG Americas Securities sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 26,042 shares — an estimated $1.88M sold.
SG Americas Securities first reported a position in RNAM in Q1 2021 and held it in 16 quarters. The position peaked at $3.93M in Q2 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- SG Americas Securities reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- SG Americas Securities sold 26,042 Avidity Biosciences shares in Q1 2026, an estimated $1.88M.
- SG Americas Securities first reported a position in Avidity Biosciences in Q1 2021 and held it in 16 quarters.
- SG Americas Securities's Avidity Biosciences position peaked at $3.93M in Q2 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.